Regeneron Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript
Good morning. My name is Carter Gould, senior biotech analyst here at UBS. Next up is Regeneron Pharmaceuticals. Joining me onstage, Marion McCourt, SVP of Commercial; Jay Markowitz, Head of Portfolio Strategy. Both, thank you very much for joining us today. I'm going to keep going back and forth with the -- so like I said, thank you.
Questions & Answers
I guess first question, we've got a lot to get through because you guys are one of the more diversified companies, lots of dynamic stuff to talk about.
I guess first thing, Jay, a question for you. You've been in the company around 3 years now, sort of you're -- over that 3 years, we've seen oncology really increase as a point of focus for the company. Can you maybe -- starting with Libtayo and then the bispecifics and the evolution of that and when I looked at sort of like your Phase I programs over the past year,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
